← Back to Screener
Kairos Pharma, Ltd. (KAPA)
Price$0.63
Favorite Metrics
Price vs S&P 500 (26W)-56.02%
Price vs S&P 500 (4W)-7.47%
Market Capitalization$13.10M
All Metrics
Book Value / Share (Quarterly)$0.30
P/TBV (Annual)2.35x
Cash Flow / Share (Quarterly)$-0.17
Price vs S&P 500 (YTD)-18.00%
EPS (TTM)$-0.30
10-Day Avg Trading Volume0.06M
EPS Excl Extra (TTM)$-0.30
EPS (Annual)$-0.30
ROI (Annual)-85.90%
Cash / Share (Quarterly)$0.22
ROA (Last FY)-83.29%
EBITD / Share (TTM)$-0.29
Cash Flow / Share (Annual)$-0.17
P/B Ratio2.07x
P/B Ratio (Quarterly)2.33x
Net Income / Employee (Annual)$-5
Net Interest Coverage (TTM)-2.03x
ROA (TTM)-74.58%
EPS Incl Extra (Annual)$-0.30
Current Ratio (Annual)27.07x
Quick Ratio (Quarterly)26.81x
3-Month Avg Trading Volume0.40M
52-Week Price Return-32.60%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.30
52-Week High$2.11
EPS Excl Extra (Annual)$-0.30
26-Week Price Return-47.28%
Quick Ratio (Annual)26.81x
13-Week Price Return-28.88%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)27.07x
Enterprise Value$8.604
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.22
3-Month Return Std Dev62.40%
Net Income / Employee (TTM)$-5
ROE (Last FY)-85.90%
Net Interest Coverage (Annual)-2.01x
EPS Basic Excl Extra (Annual)$-0.30
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.30
ROI (TTM)-80.30%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.30
Price vs S&P 500 (52W)-67.69%
Year-to-Date Return-13.86%
5-Day Price Return4.55%
EPS Normalized (Annual)$-0.30
ROA (5Y Avg)-138.86%
Month-to-Date Return9.41%
EBITD / Share (Annual)$-0.29
LT Debt / Equity (Annual)0.00x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.30
P/TBV (Quarterly)2.35x
P/B Ratio (Annual)2.33x
Book Value / Share (Annual)$0.30
Price vs S&P 500 (13W)-31.75%
Beta0.96x
P/FCF (Annual)161.67x
Revenue / Share (TTM)$0.00
ROE (TTM)-80.30%
52-Week Low$0.40
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.11
4.11
4.11
4.11
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
KAPAKairos Pharma, Ltd. | — | — | — | — | $0.63 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Kairos Pharma is a clinical-stage biopharmaceutical company developing cancer immunotherapies designed to overcome immune suppression and drug resistance. Its pipeline includes antibody and small molecule candidates targeting prostate cancer, lung cancer, breast cancer, and glioblastoma.